GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.

09.05.13 GlycoVaxyn AG to Present at the 9th Annual National Carbohydrate Symposium in Banff 06.03.13 GlycoVaxyn AG Announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors 04.01.13 GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration with Janssen Pharmaceuticals, Inc.

GlycoVaxyn will be present during:

- BioEquity Europe 2013 in Stockholm on May 22-23, 2013

- 9th Annual National Carbohydrate Symposium in Banff on May 08-10, 2013

- BIO International Convention in Chicago on April 22-25, 2013